Clinical trials: Anticoagulant
Atrial Fibrillation
Assessment of Atrial Fibrillation in Emergency Department
Atrial Fibrillation (AF) is the most common disorder of the rhythm disturbance, especially in older adults. The incidence and prevalence of AF increases significantly with age: less than one new case per 1000/year before age 40…
- Trial name
- ACFA (NCT03836339)
- Where
- France
- Volunteers
- 1,369 people
- Sponsor
- RESCUe - RESeau Cardiologie Urgence / RESUVal - RESeau des Urgences de la vallée du Rhône
Coagulation Disorder
Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects
A single centre, double-blind, randomized, parallel group, placebo-controlled study in healthy subjects conducted in two parts: Part 1: Single ascending doses in healthy subjects aged 18 to 49 years to assess safety…
- Trial name
- NCT05152420
- Testing
- VMX-C001, Apixaban, Rivaroxaban
- Where
- Netherlands
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VarmX B.V.
Non-valvular Atrial Fibrillation
A Nationwide Observational Study Looking at Effectiveness and Bleeding Complications of NOACs vs. VKA in Non-valvular Atrial Fibrillation Patients.
Using mandatory nationwide registries and possibly hospital electronic medical records in Norway, the researchers want to understand how well a group of drugs called "non-vitamin K antagonist oral anticoagulants" (rivaroxaban …
- Trial name
- PROTECT-AF (NCT03715725)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban (Eliquis), Dabigatran etexilate (Pradaxa)
- Where
- Norway
- Volunteers
- 70,000 people
- Sponsor
- Bayer
Left Sided Heart Failure, Left Ventricular Assist Device
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD].
- Conditions
- Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding
- Trial name
- VAD-ANTIX (NCT03143569)
- Testing
- aPTT guided heparin management, Anti-factor Xa guided heparin management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Atrial Fibrillation
Non-vitamin K Oral Anticoagulants in Cardioversion
Non-vitamin K oral anticoagulants (NOAC) have been shown to be safe and effective alternatives to warfarin for stroke prevention in patients with nonvalvular AF (NVAF).
- Trial name
- FinCV3 (NCT02911545)
- Volunteers
- 1,000 people
- Sponsor
- Helsinki University Central Hospital
Left Ventricular Thrombus
LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus
The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of…
- Trial name
- LVT Duration (NCT07246005)
- Testing
- Continue rivaroxaban or apixaban or warfarin, Discontinue rivaroxaban or apixaban or warfarin
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Queen Mary University of London
Direct Acting Anticoagulant Adverse Reaction, Needle Injury
Ultrasound Evaluation of Hematoma Risk After Needle EMG in Patient on DOAC Therapy
Approximately 30 minutes after needle EMG, patients who are taking direct oral anticoagulants (DOACs) will undergo an ultrasound examination to evaluate for the presence of possible intramuscular hematomas at the muscles where…
- Conditions
- Direct Acting Anticoagulant Adverse Reaction, Needle Injury, EMG, Peripheral Neuropathies
- Trial name
- U-HAND (NCT07166302)
- Where
- 2 sites in Czechia
- Volunteers
- 70 people
- Sponsor
- Masaryk University
Severe Bleeding, Urgent Surgery
Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists
Patients treated with Vitamin K antagonists (VKA) or direct oral anticoagulants as Rivaroxaban, Apixaban, Edoxaban or Dabigatran, who experience severe bleeding and/or need urgent interventions/operations that cannot wait are…
- Trial name
- RADOA (NCT01722786)
- Where
- Germany
- Volunteers
- 272 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Deep Venous Thrombosis, Pulmonary Embolism
Drug Interaction Between Paracetamol and Warfarin
The objective of this study is to investigate whether paracetamol, given at therapeutic doses (2g/day and 3 g/day), may potentiate the anticoagulant effect of warfarin.
- Conditions
- Deep Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Stroke
- Trial name
- INPAWA2 (NCT01104337)
- Testing
- paracetamol
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Hopital Lariboisière
Stroke, Ischemic Stroke
Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation
Patients who have recently had an ischemic stroke with no clear cause might have undetected atrial fibrillation (AF) that isn't caught during their initial hospital stay.
- Conditions
- Stroke, Ischemic Stroke, Cerebral Infarction, Atrial Fibrillation
- Trial name
- SPICAF (NCT06486792)
- Testing
- Apixaban, Aspirin
- Where
- France
- Volunteers
- 1,148 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolic Disease
Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study
The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first…
- Trial name
- NCT03887806
- Where
- France
- Volunteers
- 300 people
- Sponsor
- University Hospital, Strasbourg, France
Atrial Fibrillation
Health-related Quality of Life in Patients on Anticoagulants
The present study has been designed to describe the health-related quality of life in patients with non valvular atrial fibrillation who have been prescribed a specific anticoagulant treatment for their non valvular atrial…
- Trial name
- RE-QUOL (NCT03134911)
- Testing
- DOAC or VKA, VKA
- Where
- 39 sites in Spain
- Volunteers
- 535 people
- Sponsor
- Boehringer Ingelheim
Atrial Fibrillation, Heart Failure
Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure
Observational study of elderly individuals diagnosed with Non-Valvular Atrial Fibrillation and Heart Failure who are beginning oral blood thinners
- Trial name
- NCT03508271
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 60,000 people
- Sponsor
- Bristol-Myers Squibb
Deep Vein Thrombosis
Absence of Residual Vein Thrombosis Permits to Withdrawn Oral Anticoagulants
Background. The optimal duration of oral anticoagulant treatment in patients with idiopathic Deep Vein Thrombosis (DVT)of the lower limbs is still uncertain.
- Trial name
- Exten-DACUS (NCT00623987)
- Testing
- warfarin accordingly INR value
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Myeloproliferative Neoplasm
Use of Direct Oral Anticoagulants (DOACs) in Patients With Ph-negative Myeloproliferative Neoplasms
Patients with myeloproliferative neoplasms (MPN) are predisposed to have an increased thrombotic and hemorrhagic risk and, in this context, the use of newly approved direct oral anticoagulants (DOACs) may have improved bleeding…
- Trial name
- MPN-DOACs (NCT04192916)
- Testing
- DOACs
- Where
- 18 sites in United States, Canada and 5 more
- Volunteers
- 442 people
- Sponsor
- FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Therapeutic Plasma Exchange, Anticoagulant Therapy
Evaluation of Complication Rates Using Filter vs. Centrifuge and Heparin vs. Citrate Anticoagulation
Despite its growing use across the world, and similar efficacy, filter-based therapeutic plasma exchange (TPE) continues to be used less often that centrifuge-based TPE.
- Trial name
- NCT04351438
- Testing
- Active Comparator: centrifuge TPE with citrate, Active Comparator: Filter TPE with heparin, Active comparator: Filter TPE with citrate
- Where
- United States
- Volunteers
- 108 people
- Sponsor
- University of Alabama at Birmingham
Atrial Fibrillation, Stroke
DOAC in Chinese Patients With Atrial Fibrillation
Direct oral anticoagulants (DOACs) have emerged as safe and efficacious ischemic stroke prophylaxis for non-valvular atrial fibrillation (NVAF).
- Conditions
- Atrial Fibrillation, Stroke, Stroke, Acute, Brain Diseases
- Trial name
- DOAC-REAL (NCT05378035)
- Testing
- Blood Tests
- Where
- Hong Kong
- Volunteers
- 427 people
- Sponsor
- Chinese University of Hong Kong
Blood Coagulation Disorders, Acute Major Bleeding
Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy
The purpose of this study is to evaluate efficacy, safety and tolerance of BERIPLEX® P/N (Kcentra) compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate…
- Trial name
- NCT00708435
- Testing
- Beriplex® P/N (Kcentra), Fresh frozen plasma
- Where
- 69 sites in United States, Belarus and 4 more
- Volunteers
- 216 people
- Sponsor
- CSL Behring
High Risk Pregnancy, Pregnancy Complications
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
This treatment trial evaluates the addition of an anti-tumor necrosis factor-alpha drug, certolizumab, to usual treatment (a heparin agent and low-dose aspirin) in pregnant women with antiphospholipid syndrome (APS) and…
- Conditions
- High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder
- Trial name
- NCT03152058
- Testing
- Certolizumab Pegol
- Where
- 3 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- David Ware Branch
Anticoagulants and Bleeding Disorders
DAPHNE Study: Direct Anticoagulant PHarmacogeNEtic
New/direct oral anticoagulants (NOAC/DOAC), like apixaban and rivaroxaban, are an interesting alternative to unfractionated or low molecular weight heparin relayed by oral anti-vitamin K anticoagulants (VKA) for the treatment of…
- Trial name
- DAPHNE (NCT03112525)
- Testing
- CYP3A4/5 and P-gp phenotyping, CYP3A4/5 and P-gp genotyping
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- University Hospital, Geneva